China NMPA Drug Inspection - Nanyang Fanglin Traditional Chinese Medicine Pieces Co., Ltd. - Bupleurum chinense
China NMPA drug inspection for Nanyang Fanglin Traditional Chinese Medicine Pieces Co., Ltd. published April 28, 2016. Drug: Bupleurum chinense. The Inner Mongolia Autonomous Region Food and Drug Administration announced findings in April 2016 from drug quality ins
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Nanyang Fanglin Traditional Chinese Medicine Pieces Co., Ltd. published April 28, 2016. Drug: Bupleurum chinense. The Inner Mongolia Autonomous Region Food and Drug Administration announced findings in April 2016 from drug quality ins
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox